

Ultrasound-Guided Renal Biopsy: A Safe and Effective Diagnostic Tool

Introduction

Ultrasound-guided renal biopsy is a cornerstone diagnostic procedure in nephrology, providing critical histopathological information for the evaluation of medical renal diseases. It is commonly indicated in patients with unexplained acute or chronic kidney disease, nephrotic or nephritic syndromes, persistent proteinuria, or hematuria of unclear origin [1,2]. The introduction of real-time ultrasound guidance has significantly improved the safety and accuracy of renal biopsies, replacing blind techniques and reducing procedure-related complications. This approach allows precise localization of renal tissue while minimizing injury to surrounding structures.

Discussion

The procedure is typically performed percutaneously under local anesthesia, with the patient positioned prone for native kidney biopsy or supine for transplanted kidneys. Ultrasound is used to identify kidney size, depth, and cortical thickness, as well as to select an optimal biopsy site, usually the lower pole of the kidney to reduce the risk of vascular injury. Real-time imaging enables continuous visualization of the biopsy needle, ensuring accurate tissue sampling and reducing the likelihood of inadvertent complications [3,4].

Ultrasound-guided renal biopsy has a high diagnostic yield, as it allows acquisition of adequate cortical tissue containing glomeruli necessary for light microscopy, immunofluorescence, and electron microscopy. Automated spring-loaded biopsy devices have further enhanced sample quality and procedural efficiency. Compared with earlier techniques, ultrasound guidance has been associated with lower rates of major complications, such as significant bleeding, arteriovenous fistula formation, and need for surgical intervention.

Despite its safety profile, ultrasound-guided renal biopsy is not without risk. Minor complications, including localized pain and small perinephric hematomas, are relatively common but usually self-limited. Careful patient selection and pre-procedural assessment are essential, with attention to blood pressure control, coagulation status, and renal anatomy. Post-procedure monitoring with bed rest and follow-up imaging or laboratory testing helps detect early complications and ensures patient safety [5].

Conclusion

Ultrasound-guided renal biopsy is an indispensable diagnostic technique that plays a vital role in the evaluation and management of renal diseases. Its real-time imaging capability enhances accuracy while significantly reducing procedural risks compared with blind biopsy methods. When performed by experienced clinicians with appropriate patient preparation and monitoring, it provides valuable diagnostic information with a high safety margin. As imaging technology and biopsy devices continue to advance, ultrasound-guided renal biopsy will remain a fundamental tool in nephrology, supporting precise diagnosis and guiding effective, individualized patient care.

Sofia Alvarez*

Dept. of Diagnostic Nephrology, Universidad Medica Centra, Spain

*Author for correspondence:
sofia.alvarez@umc.es

Received: 01-Apr-2025, Manuscript No. oain-26-184851; **Editor assigned:** 03-Apr-2025, PreQC No. oain-26-184851 (PQ); **Reviewed:** 17-Apr-2025, QC No. oain-26-184851; **Revised:** 22-Apr-2025, Manuscript No. oain-26-184851 (R); **Published:** 28-Apr-2025, DOI: 10.37532/oain.2025.8(1).364-365

References

1. Goldstein EJ, Spellberg B, Walsh TJ, Kontoyiannis DP, Edwards Jr J, et al. (2009) Recent advances in the management of mucormycosis: from bench to bedside. *Clin Infect Dis* 48: 1743.
2. Ibrahim AS, Spellberg B, Walsh TJ, Kontoyiannis DP (2012) Pathogenesis of mucormycosis. *Clin Infect Dis* 54: 16-22.
3. Skiada A, Lass-Floerl C, Klimko N, Ibrahim A, Roilides E, et al. (2018) Challenges in the diagnosis and treatment of mucormycosis. *Med Mycol* 56: 93-101.
4. Baldin C, Soliman SSM, Jeon HH, Alkhazraji S, Gebremariam T, et al. (2018) PCR-Based Approach Targeting Mucorales-Specific Gene Family for Diagnosis of Mucormycosis. *J Clin Microbiol* 56: 746-818.
5. Spanakis EK, Aperis G, Mylonakis E (2006) New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage. *Clin Infect Dis* 43: 1060.